Heart failure and related morbidity and mortality are increasing at an alarming rate, in large
part, because of increases in aging, obesity, and diabetes mellitus. The clinical outcomes …

Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of
morbidity and mortality in patients with established disease. Secular trends in the …

Background: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that reduces the risk
of cardiovascular events. We report the effects on heart failure (HF) and cardiovascular …

The prevalence of Type 2 diabetes mellitus (T2DM) has reached pandemic proportions.
T2DM frequently causes macrovascular and/or microvascular pathologic changes and …

CORRESPONDENCE> 276 participants because 8 patients experienced a first HF event of>
1 type (eg, unknown EF event in year 1 followed by reduced EF event in year 2). Participants …

Diabetes has recently become the leading cause of death worldwide. So far, there is no
effective treatment to cure or prevent diabetes. Still, reasonable blood control through …

Aims The primary objective of this systematic review was to estimate the prevalence and
temporal changes in chronic comorbid conditions reported in heart failure (HF) clinical trials …

Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of
morbidity and mortality in patients with established disease. Secular trends in the …

Diabetes microangiopathy, a hallmark complication of diabetes, is characterised by
structural and functional abnormalities within the intricate network of microvessels beyond …

Abstract Purpose of Review Heart failure with preserved ejection fraction (HFpEF) is a
relatively new disease entity used in medical terminology; however, both the number of …